BIOGEN INC. Increase (Decrease) in Equity Securities, FV-NI
BIOGEN INC. (BIIB) reported Increase (Decrease) in Equity Securities, FV-NI of $19.00 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-04-29.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi · last filed 2026-04-29
- BIOGEN INC. increase (decrease) in equity securities, fv-ni for the quarter ending 2026-03-31 was $19.00M.
- BIOGEN INC. increase (decrease) in equity securities, fv-ni for the quarter ending 2025-12-31 was $14.40M.
- BIOGEN INC. increase (decrease) in equity securities, fv-ni for the quarter ending 2025-09-30 was -$500.00K, a 101.29% decline year-over-year.
- BIOGEN INC. increase (decrease) in equity securities, fv-ni for the quarter ending 2025-06-30 was $7.70M.
- BIOGEN INC. increase (decrease) in equity securities, fv-ni for fiscal 2025 was -$19.30M.
- BIOGEN INC. increase (decrease) in equity securities, fv-ni for fiscal 2024 was -$101.40M.
- BIOGEN INC. increase (decrease) in equity securities, fv-ni for fiscal 2023 was -$277.10M.
- BIOGEN INC. increase (decrease) in equity securities, fv-ni for fiscal 2022 was -$265.90M.
| Period end | Increase (Decrease) in Equity Securities, FV-NI 3 month | Increase (Decrease) in Equity Securities, FV-NI 6 month | Increase (Decrease) in Equity Securities, FV-NI 9 month | Increase (Decrease) in Equity Securities, FV-NI 12 month |
|---|---|---|---|---|
| 2026-03-31 | $19.00M 10-Q · filed 2026-04-29 | $33.40M derived: sum of 2 quarters · filed 2026-04-29 | $32.90M derived: sum of 3 quarters · filed 2026-04-29 | $40.60M derived: sum of 4 quarters · filed 2026-04-29 |
| 2025-12-31 | $14.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-06 | $13.90M derived: sum of 2 quarters · filed 2026-02-06 | $21.60M derived: sum of 3 quarters · filed 2026-02-06 | -$19.30M 10-K · filed 2026-02-06 |
| 2025-09-30 | -$500.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $7.20M derived: sum of 2 quarters · filed 2025-10-30 | -$33.70M 10-Q · filed 2025-10-30 | -$112.40M derived: sum of 4 quarters · filed 2026-04-29 |
| 2025-06-30 | $7.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-31 | -$33.20M 10-Q · filed 2025-07-31 | -$111.90M derived: sum of 3 quarters · filed 2026-04-29 | -$73.00M derived: sum of 4 quarters · filed 2026-04-29 |
| 2025-03-31 | -$40.90M 10-Q · filed 2026-04-29 | -$119.60M derived: sum of 2 quarters · filed 2026-04-29 | -$80.70M derived: sum of 3 quarters · filed 2026-04-29 | -$111.00M derived: sum of 4 quarters · filed 2026-04-29 |
| 2024-12-31 | -$78.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-06 | -$39.80M derived: sum of 2 quarters · filed 2026-02-06 | -$70.10M derived: sum of 3 quarters · filed 2026-02-06 | -$101.40M 10-K · filed 2026-02-06 |
| 2024-09-30 | $38.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $8.60M derived: sum of 2 quarters · filed 2025-10-30 | -$22.70M 10-Q · filed 2025-10-30 | -$24.10M derived: sum of 4 quarters · filed 2026-02-06 |
| 2024-06-30 | -$30.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-31 | -$61.60M 10-Q · filed 2025-07-31 | -$63.00M derived: sum of 3 quarters · filed 2026-02-06 | -$365.50M derived: sum of 4 quarters · filed 2026-02-06 |
| 2024-03-31 | -$31.30M 10-Q · filed 2025-05-01 | -$32.70M derived: sum of 2 quarters · filed 2026-02-06 | -$335.20M derived: sum of 3 quarters · filed 2026-02-06 | -$228.80M derived: sum of 4 quarters · filed 2026-02-06 |
| 2023-12-31 | -$1.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-06 | -$303.90M derived: sum of 2 quarters · filed 2026-02-06 | -$197.50M derived: sum of 3 quarters · filed 2026-02-06 | -$277.10M 10-K · filed 2026-02-06 |
| 2023-09-30 | -$302.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-30 | -$196.10M derived: sum of 2 quarters · filed 2024-10-30 | -$275.70M 10-Q · filed 2024-10-30 | -$381.30M derived: sum of 4 quarters · filed 2025-02-12 |
| 2023-06-30 | $106.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $26.80M 10-Q · filed 2024-08-01 | -$78.80M derived: sum of 3 quarters · filed 2025-02-12 | $30.20M derived: sum of 4 quarters · filed 2025-02-12 |
| 2023-03-31 | -$79.60M 10-Q · filed 2024-04-24 | -$185.20M derived: sum of 2 quarters · filed 2025-02-12 | -$76.20M derived: sum of 3 quarters · filed 2025-02-12 | -$154.40M derived: sum of 4 quarters · filed 2025-02-12 |
| 2022-12-31 | -$105.60M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-12 | $3.40M derived: sum of 2 quarters · filed 2025-02-12 | -$74.80M derived: sum of 3 quarters · filed 2025-02-12 | -$265.90M 10-K · filed 2025-02-12 |
| 2022-09-30 | $109.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $30.80M derived: sum of 2 quarters · filed 2023-11-08 | -$160.30M 10-Q · filed 2023-11-08 | -$276.60M derived: sum of 4 quarters · filed 2024-02-14 |
| 2022-06-30 | -$78.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-07-25 | -$269.30M 10-Q · filed 2023-07-25 | -$385.60M derived: sum of 3 quarters · filed 2024-02-14 | -$812.50M derived: sum of 4 quarters · filed 2024-02-14 |
| 2022-03-31 | -$191.10M 10-Q · filed 2023-04-25 | -$307.40M derived: sum of 2 quarters · filed 2024-02-14 | -$734.30M derived: sum of 3 quarters · filed 2024-02-14 | -$580.30M derived: sum of 4 quarters · filed 2024-02-14 |
| 2021-12-31 | -$116.30M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-14 | -$543.20M derived: sum of 2 quarters · filed 2024-02-14 | -$389.20M derived: sum of 3 quarters · filed 2024-02-14 | -$826.80M 10-K · filed 2024-02-14 |
| 2021-09-30 | -$426.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-25 | -$272.90M derived: sum of 2 quarters · filed 2022-10-25 | -$710.50M 10-Q · filed 2022-10-25 | $13.10M derived: sum of 4 quarters · filed 2023-02-15 |
| 2021-06-30 | $154.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-07-20 | -$283.60M 10-Q · filed 2022-07-20 | $440.00M derived: sum of 3 quarters · filed 2023-02-15 | $358.50M derived: sum of 4 quarters · filed 2023-02-15 |
| 2021-03-31 | -$437.60M 10-Q · filed 2022-05-03 | $286.00M derived: sum of 2 quarters · filed 2023-02-15 | $204.50M derived: sum of 3 quarters · filed 2023-02-15 | $306.20M derived: sum of 4 quarters · filed 2023-02-15 |
| 2020-12-31 | $723.60M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-15 | $642.10M derived: sum of 2 quarters · filed 2023-02-15 | $743.80M derived: sum of 3 quarters · filed 2023-02-15 | $681.80M 10-K · filed 2023-02-15 |
| 2020-09-30 | -$81.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-20 | $20.20M derived: sum of 2 quarters · filed 2021-10-20 | -$41.80M 10-Q · filed 2021-10-20 | -$84.30M derived: sum of 4 quarters · filed 2022-02-03 |
| 2020-06-30 | $101.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-22 | $39.70M 10-Q · filed 2021-07-22 | -$2.80M derived: sum of 3 quarters · filed 2022-02-03 | -$12.20M derived: sum of 4 quarters · filed 2022-02-03 |
| 2020-03-31 | -$62.00M 10-Q · filed 2021-04-22 | -$104.50M derived: sum of 2 quarters · filed 2022-02-03 | -$113.90M derived: sum of 3 quarters · filed 2022-02-03 | -$289.70M derived: sum of 4 quarters · filed 2022-02-03 |
| 2019-12-31 | -$42.50M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-03 | -$51.90M derived: sum of 2 quarters · filed 2022-02-03 | -$227.70M derived: sum of 3 quarters · filed 2022-02-03 | $147.30M 10-K · filed 2022-02-03 |
| 2019-09-30 | -$9.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-21 | -$185.20M derived: sum of 2 quarters · filed 2020-10-21 | $189.80M 10-Q · filed 2020-10-21 | $177.70M derived: sum of 4 quarters · filed 2021-02-03 |
| 2019-06-30 | -$175.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-22 | $199.20M 10-Q · filed 2020-07-22 | $187.10M derived: sum of 3 quarters · filed 2021-02-03 | $325.00M derived: sum of 4 quarters · filed 2021-02-03 |
| 2019-03-31 | $375.00M 10-Q · filed 2020-04-23 | $362.90M derived: sum of 2 quarters · filed 2021-02-03 | $500.80M derived: sum of 3 quarters · filed 2021-02-03 | |
| 2018-12-31 | -$12.10M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-03 | $125.80M derived: sum of 2 quarters · filed 2021-02-03 | $124.80M 10-K · filed 2021-02-03 | |
| 2018-09-30 | $137.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-22 | $136.90M 10-Q · filed 2019-10-22 | ||
| 2018-06-30 | -$1.00M 10-Q · filed 2019-07-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |